DXCMHealthcare · Medical DevicesThe 28 Wall Street analysts covering DexCom, Inc. hold a median 12-month price target of $94 — +4.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 2 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores DexCom, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (99): The share count has been shrinking and the company is not leaning on new borrowing.
Momentum (65): The shares have been drifting down relative to others.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DXCM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +4.8% from it.
Of the 20 most recent actions, 14 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Aug 2026 | Argus Research | Maintains | Buy | $86 → $96 |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Buy | $82 → $90 |
| 31 July 2026 | Benchmark | Maintains | Buy | $77 → $82 |
| 31 July 2026 | BTIG | Maintains | Buy | $80 → $90 |
| 31 July 2026 | Citigroup | Maintains | Buy | $84 → $88 |
| 31 July 2026 | JP Morgan | Maintains | Neutral | $65 → $82 |
| 31 July 2026 | Mizuho | Maintains | Outperform | $90 → $95 |
| 31 July 2026 | Piper Sandler | Reiterates | Overweight | $88 → $95 |
| 31 July 2026 | RBC Capital | Maintains | Outperform | $85 → $90 |
| 31 July 2026 | Stifel | Maintains | Buy | $90 → $95 |
| 31 July 2026 | Truist Securities | Maintains | Buy | $87 → $93 |
| 31 July 2026 | Wells Fargo | Maintains | Overweight | $85 → $90 |
| 28 July 2026 | UBS | Reinstates | Buy | $96 |
| 16 July 2026 | Truist Securities | Maintains | Buy | $80 → $87 |
| 16 July 2026 | Truist Securities | Maintains | Buy | — |
| 15 July 2026 | Mizuho | Maintains | Outperform | $85 → $90 |
| 15 July 2026 | Mizuho | Maintains | Outperform | — |
| 23 June 2026 | Deutsche Bank | Initiates | Buy | $86 |
| 23 June 2026 | Deutsche Bank | Initiates | Buy | — |
| 15 June 2026 | Piper Sandler | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DXCM appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, DexCom, Inc. returned +13.7% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 22% of US stocks
Cheaper than 19% of US stocks
Cheaper than 8% of US stocks
Cheaper than 12% of US stocks
Higher than 59% of US stocks
Higher than 71% of US stocks
Higher than 77% of US stocks
Higher than 83% of US stocks
Higher than 82% of US stocks
Higher than 91% of US stocks
Higher than 92% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
DexCom, Inc. has a market value of $34.0B and an enterprise value of $33.5B.
Revenue in the twelve months to 30 June 2026: $5.0B. The latest quarter grew 13.1% year on year.
Net income over the same four quarters: $999.7M, a 20.1% net margin.
Diluted earnings per share, trailing twelve months: $2.53.
Free cash flow in the twelve months to 30 June 2026: $1.4B.
Trailing P/E: 35.6×; forward P/E: 28.9× — the forward figure prices analyst consensus estimates, not reported earnings.
DexCom, Inc. employs 11,000 people — $452K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own DexCom, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Barrons revisits stock picks including Dexcom, Bristol Myers Squibb, and Quanta Services, noting that technical indicators have turned bullish for the three stocks.
Why it matters — For DXCM watchers, this signals a potential improvement in the stock's technical outlook as assessed by the publication.
Zacks Investment Research highlights DexCom (DXCM) as a top growth stock for the long term, referencing its Zacks Style Scores feature designed to help investors identify strong stocks.
Why it matters — DXCM watchers would note that the company is being singled out favorably by Zacks' research framework as a strong long-term growth candidate.
DexCom announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at approximately 8:00 AM EDT. The presentation will be webcast concurrently and archived on the Dexcom Investor Relations website.
Why it matters — Dexcom watchers would care because the presentation offers an opportunity to hear management's latest update on the company in a public forum, with the archived webcast providing a reference for investors.
A Zacks Investment Research article compares Abbott (ABT) and DexCom (DXCM) as CGM stock picks, noting that Abbott edges DexCom on price-target upside and valuation. Both companies are pursuing continuous glucose monitoring growth through innovation, adoption, and strong liquidity.
Why it matters — A DXCM watcher would care because the article positions DexCom as trailing Abbott on valuation and price-target upside, directly informing how the stock is viewed relative to a key competitor.
Zacks Investment Research identifies DexCom (DXCM) as a strong momentum stock using its Style Scores system, which helps investors find top-rated stocks based on investing style. The article promotes using this scoring tool to identify such momentum names.
Why it matters — For DXCM watchers, the report signals that the stock is favorably rated on momentum by Zacks' style-based scoring framework.
The 28 Wall Street analysts covering DexCom, Inc. have a median 12-month price target of $94, with estimates ranging from $79 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 28 analysts covering DexCom, Inc., 25 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DexCom, Inc. 99 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, DexCom, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (99 of 100).
No one can know that. What the data says: the median 12-month target from 28 analysts implies +4.8% from the last close, and Ticker Nerd's factor model ranks DexCom, Inc. 99 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering DexCom, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DXCM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $79 to $115 over the next 12 months.
DexCom, Inc. returned +13.7% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
DexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health.
The most recent item we track (Barrons, 3 Sept 2026): "Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services". Barrons revisits stock picks including Dexcom, Bristol Myers Squibb, and Quanta Services, noting that technical indicators have turned bullish for the three stocks.
DexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health. Dexcom develops wearable biosensors, transmitters, receivers, and software that provide real-time glucose readings, trend data, and alerts to help users and clinicians monitor glucose levels without routine fingerstick testing. Its current product lineup includes Dexcom G7, Dexcom G7 15 Day, Dexcom G6, Dexcom ONE+, Stelo, Dexcom Share, and Dexcom Follow, along with digital tools and remote monitoring features that support daily diabetes management. The company serves people with diabetes, adults with prediabetes and type 2 diabetes who do not use insulin, and healthcare professionals across the United States and international markets. Headquartered in San Diego, California, DexCom plays a significant role in the diabetes care technology market through its focus on connected glucose sensing and data-sharing solutions.
CEO Mr. Jacob Steven Leach · 11,000 employees · United States · https://www.dexcom.com
